In Vitro Profiling of Pramiconazole and In Vivo Evaluation in Microsporum canis Dermatitis and Candida albicans Vaginitis Laboratory Models

被引:12
作者
de Wit, Kelly [1 ]
Paulussen, Caroline [1 ]
Matheeussen, An [1 ]
van Rossem, Koen [2 ]
Cos, Paul [1 ]
Maes, Louis [1 ]
机构
[1] Univ Antwerp, Fac Pharmaceut Biomed & Vet Sci, Lab Microbiol Parasitol & Hyg LMPH, B-2020 Antwerp, Belgium
[2] Stiefel, Res Triangle Pk, NC USA
关键词
FUNGAL-INFECTIONS; ORAL TREATMENT; EFFICACY;
D O I
10.1128/AAC.00730-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The triazole antifungal pramiconazole (Stiefel, a GSK company) was compared with itraconazole, miconazole, and terbinafine in vitro and in vivo. Potent in vitro activities against Candida spp. (50% inhibitory concentration [IC50], 0.04 to 1.83 mu M) and Microsporum and Trichophyton spp. (IC50, 0.15 to 1.34 mu M) were obtained but not, however, against other filamentous molds and zygomycetes. In the M. canis guinea pig model and C. albicans vulvovaginitis rat model, pramiconazole was superior to the reference compounds after oral and topical administration.
引用
收藏
页码:4927 / 4929
页数:3
相关论文
共 24 条
[1]   Epidemiology of superficial fungal infections [J].
Ameen, Mahreen .
CLINICS IN DERMATOLOGY, 2010, 28 (02) :197-201
[2]  
Arikan S, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1949
[3]   Absence of an active metabolite for the triazole antifungal pramiconazole [J].
Ausma, Jannie ;
Pennick, Gennethel ;
Bohets, Hilde ;
van de Velde, Vera ;
Borgers, Marcel ;
Fothergill, Annette .
ACTA DERMATO-VENEREOLOGICA, 2007, 87 (01) :22-26
[4]   Fungal infections of the skin: Infection process and antimycotic therapy [J].
Borgers, M ;
Degreef, H ;
Cauwenbergh, G .
CURRENT DRUG TARGETS, 2005, 6 (08) :849-862
[5]   Newer systemic antifungal agents - Pharmacokinetics, safety and efficacy [J].
Boucher, HW ;
Groll, AH ;
Chiou, CC ;
Walsh, TJ .
DRUGS, 2004, 64 (18) :1997-2020
[6]   Zygomycosis: the re-emerging fungal infection [J].
Chayakulkeeree, M. ;
Ghannoum, M. A. ;
Perfect, J. R. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2006, 25 (04) :215-229
[7]   Anti-infective potential of natural products: How to develop a stronger in vitro 'proof-of-concept' [J].
Cos, Paul ;
Vlietinck, Arnold J. ;
Vanden Berghe, Dirk ;
Maes, Louis .
JOURNAL OF ETHNOPHARMACOLOGY, 2006, 106 (03) :290-302
[8]   The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials [J].
Decroix, J. ;
Ausma, J. ;
Cauwenbergh, G. ;
Borgers, M. ;
Wouters, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (04) :854-856
[9]   Efficacy of a single oral dose of 200 mg pramiconazole in vulvovaginal yeast infections: An exploratory phase IIa trial [J].
Donders, Gilbert ;
Ausma, Jannie ;
Wouters, Luc ;
Cauwenbergh, Geert ;
Borgers, Marcel ;
Janssens, Dirk .
ACTA DERMATO-VENEREOLOGICA, 2008, 88 (05) :462-466
[10]   The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase II a trial [J].
Faergemann, J. ;
Ausma, J. ;
Vandeplassche, L. ;
Borgers, M. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (06) :1385-1388